• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    5/5/25 6:03:32 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NXL alert in real time by email
    false 0001527352 0001527352 2025-05-05 2025-05-05 0001527352 nxl:CommonStockParValue0.001PerShareMember 2025-05-05 2025-05-05 0001527352 nxl:WarrantsEachExercisableForOneShareOfCommonStockMember 2025-05-05 2025-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): May 5, 2025

     

    NEXALIN TECHNOLOGY, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41507   27-5566468
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1776 Yorktown, Suite 550

    Houston, TX 77056

    Registrant’s telephone number, including area code: (832) 260-0222

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   NXL   The Nasdaq Stock Market LLC
             
    Warrants, each exercisable for one share of Common Stock   NXLIW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     

       

     

     

    Item 1.01Entry into a Material Definitive Agreement.

     

    On April 29, 2025, Nexalin Technology, Inc., a Delaware corporation headquartered in Houston, Texas (the “Company”) established an “at-the-market” offering (the “ATM Program”) through which the Company may sell, from time to time through Maxim Group LLC, as exclusive sales agent (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Shares”).

     

    On May 5, 2025, in connection with the Company’s effective shelf registration statement on Form S-3 (File No. 333-286711) (the “Registration Statement”), the Company entered into Amendment No. 1 (the “Amendment”) to the equity distribution agreement, dated April 29, 2025 (the “Equity Distribution Agreement”) with the Agent. The Amendment was entered into by and between the Company and the Agent in order to reduce the maximum amount of shares of the Company’s common stock that may be issued and sold through the Agent, from an aggregate offering price from $9,777,825 to an aggregate offering price of up to $3,100,000. As of May 5, 2025, up to approximately $3,100,000 million in aggregate amount of the Shares remain available for sale under the ATM Program.

     

    Further details regarding the Equity Distribution Agreement, as amended by the Amendment, and the ATM Program are set forth in the Company’s prospectus supplement, dated May 5, 2025 (the “New ATM Prospectus Supplement”) and the accompanying prospectus, dated April 29, 2025 (together with the New ATM Prospectus Supplement, the “Prospectus”), filed by the Company with the Securities and Exchange Commission.

     

    The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference. A copy of the opinion of Warshaw Burstein relating to the legality of the issuance and sale of the Shares pursuant to the Prospectus is attached as Exhibit 5.1 hereto.

     

    The Shares, if any, will be issued pursuant to the Registration Statement dated April 29, 2025, and the New ATM Prospectus Supplement dated May 5, 2025, and the Prospectus, as supplemented from time to time.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

     

    Item 9.01.Financial Statements and Exhibits.

     

    (d)Exhibits.

     

    Exhibit  

    Description

    5.1   Opinion of Warshaw Burstein, LLP
    10.1   Amendment No. 1 to Equity Distribution Agreement

     

     1 

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NEXALIN TECHNOLOGY, INC.
       
      By: /s/ Mark White
        Mark White
        Chief Executive Officer

     

    Dated: May 5, 2025

     

     2 
    Get the next $NXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXL

    DatePrice TargetRatingAnalyst
    More analyst ratings